GPR30在卵巢癌发生发展中的变化及意义  

The effect of GPR30 on the development of ovarian cancer

作　　者：马焱[1] 刘爽[1] 亚力坤.穆罕默德 徐新燕[1] 李莉[1] 

机构地区：[1]新疆医科大学附属肿瘤医院妇外一科,乌鲁木齐830000

出　　处：《疑难病杂志》2017年第10期1043-1046,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金项目(81560423)

摘　　要：目的分析G蛋白偶联受体30(GPR30)在卵巢癌发生发展中的变化情况。方法选取2013年3月—2015年3月新疆医科大学附属肿瘤医院妇外一科治疗的上皮性卵巢癌患者75例和良性上皮性卵巢肿瘤患者45例手术标本作为研究对象,另选取75例卵巢癌标本的癌旁组织作为对照组,检测组织标本中GPR30的表达。采用免疫荧光技术和流式分选技术检测GPR30在卵巢癌的亚细胞定位。通过免疫组化法检测GPR30在卵巢癌组织、良性上皮卵巢肿瘤组织、癌旁组织中的表达。患者出院后进行追踪随访,进一步分析GPR30与卵巢癌发生发展的关系。结果免疫荧光技术和流式分选技术显示GPR30在细胞核上的表达高于细胞质上的表达(90.13%vs.70.37%,χ~2=8.654,P<0.05);上皮性卵巢癌中GPR30的高表达率明显高于良性上皮卵巢肿瘤组织和癌旁组织(分别为80.0%、53.3%、32.0%,χ~2=35.065,P<0.01);不同组织类型的上皮性卵巢癌GPR30高表达率存在差异,且临床分期中,Ⅲ~Ⅳ期上皮性卵巢癌的GPR30高表达率高于Ⅰ~Ⅱ期(86.9%vs.50.0%,χ~2=7.514,P<0.01);GPR30的高表达率复发患者高于未复发患者(94.3%vs.45.5%,χ~2=20.266,P<0.01),死亡患者高于存活患者(95.2%vs.75.9%,χ~2=4.231,P<0.05)。结论卵巢癌的发生和发展可能与GPR30的参与有关,并且与卵巢癌的侵袭和转移存在相关性,因此GPR30可作为卵巢癌的诊断和恶性程度判断依据之一。Objective To analyze the changes of GPR30 in the development of ovarian cancer.Methods A total of 120 patients with ovarian cancer treated by the Department of Ovarian Cancer were selected from March 2013 to March 2015.The expression of GPR30 in ovarian tumor tissue was detected,including 75 patients with epithelial ovarian cancer,45 cases of benign epithelial ovarian tumor tissue specimens,as the observation group,another 120 cases of normal ovarian tissue as a control group.Immunofluorescence technique and flow sorting technique were used to detect the subcellular localization of GPR30 in ovarian cancer.The expression of GPR30 in ovarian cancer tissues,benign epithelial ovarian tumor tissues,adjacent tissues and normal ovarian tissues was detected by immunohistochemistry.The patients were followed up after discharge and further analyzed the relationship between GPR30 and the development of ovarian cancer.Results The expression of GPR30 on the nucleus was higher than that of the cytoplasm （90.13% vs.70.37%,χ^2=8.654,P〈0.05）.The high expression rate of GPR30 in epithelial ovarian cancer was significantly higher than that in benign epithelial ovarian tumor and normal ovary （80.0%,53.3%,32.0%,χ^2=35.065,P〈0.05）.The high expression rate of GPR30 in epithelial ovarian cancer was different,and the high expression rate of GPR30 in epithelial ovarian cancer was higher in stage III-IV than that in stage Ⅰ-Ⅱ （86.9% vs.50.0%,χ^2=7.514,P〈0.05）.The high rate of GPR30 recurrence is higher than that of patients without recurrence（94.3% vs.45.5%,χ^2=20.266,P〈0.01）,and the death rate is higher than that of the patients （95.2% vs.75.9%,χ^2=4.231,P〈0.05）.Conclusion The occurrence and development of ovarian cancer may be related to the participation of GPR30 and the correlation with the invasion and metastasis of ovarian cancer.Therefore,GPR30 can be used as one of the basis for the diagnosis and malignant degree of ovarian cancer.

关 键 词：G蛋白偶联受体30 卵巢癌 诊断 预后 

分 类 号：R737.31[医药卫生—肿瘤]